<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nitrophorin 2 (NP2) is a 20 kDa lipocalin identified in the salivary gland of the blood sucking insect, Rhodnius prolixus </plain></SENT>
<SENT sid="1" pm="."><plain>It functions as a potent inhibitor of the intrinsic pathway of coagulation upon binding to factor IX (FIX) or FIXa </plain></SENT>
<SENT sid="2" pm="."><plain>Herein we have investigated the in vivo antithrombotic properties of NP2 </plain></SENT>
<SENT sid="3" pm="."><plain>Surface plasmon resonance assays demonstrated that NP2 binds to rat FIX and FIXa with high affinities (KD = 43 and 47 nM, respectively), and prolongs the aPTT without affecting the PT </plain></SENT>
<SENT sid="4" pm="."><plain>In order to evaluate NP2 antithrombotic effects in vivo two distinct models of <z:mp ids='MP_0005048'>thrombosis</z:mp> in rats were carried out </plain></SENT>
<SENT sid="5" pm="."><plain>In the <z:chebi fb="0" ids="52261">rose Bengal</z:chebi>/laser induced injury model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, NP2 increased the carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> time by ≍35 and ≍155%, at doses of 8 and 80 μg/kg, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>NP2 also inhibited <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in an arterio-venous shunt model, showing ≍60% reduction at 400 μg/kg (i.v </plain></SENT>
<SENT sid="7" pm="."><plain>administration) </plain></SENT>
<SENT sid="8" pm="."><plain>The antithrombotic effect lasted for up to 48 hours after a single i.v. dose </plain></SENT>
<SENT sid="9" pm="."><plain>Notably, effective doses of NP2 did not increase the blood loss as evaluated by tail-transection model </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, NP2 is a potent and long-lasting inhibitor of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> with minor effects on haemostasis </plain></SENT>
<SENT sid="11" pm="."><plain>It might be regarded as a potential agent for the treatment of human <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> </plain></SENT>
</text></document>